title: Gynecologic Oncology Group studies with ifosfamide.
abstract: The Gynecologic Oncology Group has conducted a series of phase II studies with ifosfamide and mesna since 1985. Previously untreated patients received ifosfamide 1.5 g/m2 intravenously daily for 5 days. Mesna was given intravenously every 4 hours three times daily at 20% of the daily ifosfamide dose. Because of the toxic effects observed in previously treated patients with ovarian cancer, the ifosfamide dose was reduced to 1.2 g/m2/d in patients with prior chemotherapy or radiotherapy. In epithelial ovarian cancer, responses were observed in eight (20%) of 41 evaluable patients, with three (7%) complete responses. In patients with squamous carcinoma of the cervix, an 11.1% response rate (three of 27 patients) was observed in those who had received prior platinum therapy. In 51 previously untreated patients, the response rate was 15.7%. In nonsquamous cervical carcinomas, there were three partial responses among 25 patients (12%). An 8.6% response rate was observed among 23 patients with previously treated endometrial adenocarcinomas. In uterine sarcomas, response rates were 30.7% in mixed müllerian tumors, 17.2% in leiomyosarcomas, and 27.3% in endometrial stromal sarcomas. Patients with ovarian sarcomas responded in 27.8% of cases. Studies with ifosfamide combinations are currently under way by the Gynecologic Oncology Group.
authors: Department of Obstetrics and Gynecology, Indiana University Medical Center, Indianapolis 46202.
authors: G P
authors: GP
authors: Sutton
authors: J A
authors: JA
authors: Blessing
authors: A
authors: A
authors: Manetta
authors: H
authors: H
authors: Homesley
authors: W
authors: W
authors: McGuire
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D002277:Carcinoma / Q000188:drug therapy; D017322:Clinical Trials, Phase II as Topic; D016889:Endometrial Neoplasms / Q000188:drug therapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D016879:Salvage Therapy; D012509:Sarcoma / Q000188:drug therapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000188:drug therapy
chemical_list: D007069:Ifosfamide